APA (7th ed.) Citation

SANDER-PADILLA, J. G., LUGO-SÁNCHEZ, L. A., RIOS-BRITO, K. F., RODRIGUEZ-ROCANDIO, K. E., ARGUEDAS, M. M., FLORES-HUANOSTA, D., . . . ROMERO, Y. (2024). 23-PUB: Reduction of Residual Lipid Risk in Patients with Type 2 Diabetes and Mixed Dyslipidemia Treated with a Fixed-Dose Combination of Atorvastatin/Fenofibrate. Diabetes (New York, N.Y.), 73(Supplement_1), 1. https://doi.org/10.2337/db24-23-PUB

Chicago Style (17th ed.) Citation

SANDER-PADILLA, JOSE G., LAURA A. LUGO-SÁNCHEZ, KEVIN F. RIOS-BRITO, KARLA E. RODRIGUEZ-ROCANDIO, MARÍA M. ARGUEDAS, DIANA FLORES-HUANOSTA, ILEANA C. RODRIGUEZ-VAZQUEZ, JORGE GONZALEZ-CANUDAS, and YULIA ROMERO. "23-PUB: Reduction of Residual Lipid Risk in Patients with Type 2 Diabetes and Mixed Dyslipidemia Treated with a Fixed-Dose Combination of Atorvastatin/Fenofibrate." Diabetes (New York, N.Y.) 73, no. Supplement_1 (2024): 1. https://doi.org/10.2337/db24-23-PUB.

MLA (9th ed.) Citation

SANDER-PADILLA, JOSE G., et al. "23-PUB: Reduction of Residual Lipid Risk in Patients with Type 2 Diabetes and Mixed Dyslipidemia Treated with a Fixed-Dose Combination of Atorvastatin/Fenofibrate." Diabetes (New York, N.Y.), vol. 73, no. Supplement_1, 2024, p. 1, https://doi.org/10.2337/db24-23-PUB.